In case you missed it, prices for newly launched U.S. pharmaceuticals have more
than doubled last year compared to 2021 according to a new Reuters analysis. Of
the 45 medicines surveyed in 2024, the median annual list price was more than
$370,000 compared to the median launch price of $300,000 in 2023 and $222,000
in 2022. A separate study published in the JAMA Network based on the same
criteria as the Reuters survey found that the media launch price for 30 drugs
was $180,000 in 2021.





 

May 23, 2025



TOPLINE



In case you missed it, prices for newly launched U.S. pharmaceuticals have
more than doubled last year compared to 2021 according to a new Reuters
analysis. Of the 45 medicines surveyed in 2024, the median annual list price
was more than $370,000 compared to the media launch price of $300,000 in 2023
and $222,000 in 2022. A separate study published in the JAMA Network based on
the same criteria as the Reuters survey found that the media launch price for
30 drugs was $180,000 in 2021.

The Reuters analysis is yet another example of Big Pharma’s setting launch
prices that are outrageously high to pad their bottom line, and the industry
shows no sign of stopping. The article quotes William Padula, a professor of
pharmaceutical and health economics at the University of Southern California,
who noted that “there is no indication that the trend will slow.”

Drugmakers are given the incentive of longer periods of market exclusivity if
they invest in research for rare diseases, allowing pharmaceutical companies to
continue to game the system and set sky-high list prices. For example, Pfizer
priced their hemophilia gene therapy drug Beqvez at a whopping $3.5 million
last year. The report found that “pharmaceutical companies say new medicines
offer cost-saving value, including potentially fewer emergency room visits and
hospital stays, and with some treatments using gene editing, the possibility of
a cure.” Despite Big Pharma’s claims of cost-saving value, their consistent
egregious launch prices for new drugs place limits access and places an
unsustainable burden on American patients.



Read the Reuters article HERE
<[link removed]>
. Read more on bipartisan, market-based solutions to hold Big Pharma accountable
HERE <[link removed]>.



QUOTE OF THE WEEK



“There's a reason why when you watch the news now, you're basically watching …
people dancing in the fields and singing with these drug ads nonstop in the
commercial breaks — because they are so expensive.”



- Martin Makary, Commissioner of the U.S. Food and Drug Administration (FDA)
<[link removed]>



DATA POINTS YOU SHOULD KNOW



$18 Billion



The pharmaceutical industry’s 2023 advertising spend in the United States,
according to areport
<[link removed]>
from the University of Pittsburgh Law Review.



TWEETS OF THE WEEK



@IMAKglobal <[link removed]>: “Merck is
changing the way Keytruda is delivered, from an IV infusion to a subcutaneous
injection, so it can thwart biosimilar competition and continue price gouging
people with cancer. It's a tactic known as “product hopping" and it's a form of
patent abuse. Here’s how it works.”



@AFergusonFTC <[link removed]>: “Today
the @FTC sent warnings to companies that have improperly listed drug patents.
Improper listings can harm competition and lead to higher drug prices.”



ROAD TO RECOVERY



Inside Health Policy: FTC Launches Third Crackdown On Orange Book Listings,
Marking First Action Under Trump Admin
<[link removed]>



The Federal Trade Commission (FTC) on Wednesday (May 21) escalated its
crackdown on what it calls improper patent listings in FDA’s Orange Book that
delay generic competition and keep drug prices high, issuing a new round of
challenges targeting more than 200 patents protecting popular brand-name
medications used to treat asthma, diabetes, chronic obstructive pulmonary
disease (COPD) and severe allergic reactions. The move marks FTC’s third wave
of such actions in under a year--and the first set of warning letters issued
since President Donald Trump took office in January.



Law360: GOP FTC Renews Calls For Orange Book Patent Delistings
<[link removed]>



The now-Republican controlled Federal Trade Commission again called on Teva,
Novartis, Mylan and other drugmakers to remove patents from a key federal
database that partially insulates their drugs from generic competition, arguing
Wednesday the patents cover "devices," not drugs, and thus don't warrant such
protection. Armed with a December Federal Circuit decision finding that several
Teva Pharmaceuticals inhaler patents don't belong in the U.S. Food and Drug
Administration's Orange Book, the FTC issued a third round of warning letters
demanding that drugmakers, including Teva, who continue to refuse to remove
their patents from the database do so now.



Endpoints News: Teva, Novartis Get Fresh Warnings From FTC Over Orange Book
Patent Listings
<[link removed]>



The FTC is continuing its campaign against drug patents that it claims are
improperly listed in an FDA database known as the Orange Book, carrying over an
approach started under the Biden administration. The antitrust regulator on
Wednesday sent a fresh round of warning letters to three Teva entities,
Novartis, Amphastar Pharmaceuticals, Viatris’ Mylan Specialty, and Covis
Pharma. The letters allege that the companies failed to remove “improperly
listed device patents” that cover treatments for asthma, diabetes and more from
the patent database.



PHARMA’S POOR PROGNOSIS



TechTarget: How GLP-1 Drug Patents Worsen Healthcare Disparities
<[link removed]>



Novo Nordisk and Eli Lilly have turned GLP-1 receptor agonists into
multibillion-dollar powerhouses, but at what cost to patients and public
health? According to I-MAK's April report, these companies use strategic patent
extensions to cement high market caps and shareholder payouts all while
deepening treatment access issues for Black Americans and other underserved
populations. Currently, glucagon-like peptide-1 (GLP-1) receptor agonists rely
on two active pharmaceutical ingredients -- semaglutide and tirzepatide.
However, they are marketed across five brands FDA-approved to treat either
diabetes (Ozempic, Rybelsus, Mounjaro) or aid in weight loss (Wegovy, Zepbound).



Reuters: Prices For New US Drugs Doubled In 4 Years As Focus On Rare Disease
Grows
<[link removed]>



U.S. prices for newly-launched pharmaceuticals more than doubled last year
compared to 2021, as companies leveraged scientific advances to develop more
therapies for rare diseases, which typically command high prices, a Reuters
analysis found. The median annual list price for a new drug was over $370,000
in 2024, according to the Reuters survey of 45 medicines. In 2021, the median
price was $180,000 for the 30 drugs first marketed through mid-July, according
to a study published in JAMA based on the same criteria. The median launch
price was $300,000 in 2023 and $222,000 in 2022.



###



























Copyright © 2019 Campaign for Sustainable Rx Pricing
Our address is 1341 G St NW, #1100, Washington, DC xxxxxx


This email was sent to [email protected]. To unsubscribe please click
here.
<[link removed]>